(a) As used in this section, "continuous glucose monitor" means an instrument or device, including repair and replacement parts, that: (1) Is designed and offered for the purpose of aiding an individual with diabetes; (2) Measures glucose levels at set intervals by means of a small electrode placed under the skin and held in place by an adhesive; and (3) Is generally not useful to an individual who has not been diagnosed with diabetes. (b) The Arkansas Medicaid Program shall provide coverage for a continuous glucose monitor for the treatment of an individual if the individual has: (1) Either: (A) A presence of type 1 diabetes or any other type of diabetes with: (i) The use of insulin more than two (2) times daily; or (ii) Evidence of Level 2 or Level 3 hypoglycemia; or (B) Diagnosis of glycogen storage disease type 1a; and (2) Regular follow-up visits with a healthcare provider at a minimum of every six (6) months to assess for ongoing benefit of the continuous glucose monitor. (c) Coverage for a continuous glucose monitor under the Arkansas Medicaid Program shall allow the beneficiary to obtain a continuous glucose monitor through a prescription at a pharmacy and be eligible for rebates as a pharmacy benefit. Added by Act 2023, No. 393,§ 2, eff. 8/1/2023. Added by Act 2023, No. 205,§ 8, eff. 8/1/2023. (a) As used in this section, "continuous glucose monitor" means an instrument or device, including repair and replacement parts, that: (1) Is designed and offered for the purpose of aiding an individual with diabetes; (2) Measures glucose levels at set intervals by means of a small electrode placed under the skin and held in place by an adhesive; and (3) Is generally not useful to an individual who has not been diagnosed with diabetes. (b) The Arkansas Medicaid Program shall provide coverage for a continuous glucose monitor for the treatment of an individual if the individual has: (1) Either: (A) A presence of type 1 diabetes or any other type of diabetes with: (i) The use of insulin more than two (2) times daily; or (ii) Evidence of Level 2 or Level 3 hypoglycemia; or (B) Diagnosis of glycogen storage disease type 1a; and (2) Regular follow-up visits with a healthcare provider at a minimum of every six (6) months to assess for ongoing benefit of the continuous glucose monitor. (c) Coverage for a continuous glucose monitor under the Arkansas Medicaid Program shall allow the beneficiary to obtain a continuous glucose monitor through a prescription at a pharmacy and be eligible for rebates as a pharmacy benefit. Added by Act 2023, No. 393,§ 2, eff. 8/1/2023. Added by Act 2023, No. 205,§ 8, eff. 8/1/2023. (a) As used in this section, "continuous glucose monitor" means an instrument or device, including repair and replacement parts, that: (1) Is designed and offered for the purpose of aiding an individual with diabetes; (2) Measures glucose levels at set intervals by means of a small electrode placed under the skin and held in place by an adhesive; and (3) Is generally not useful to an individual who has not been diagnosed with diabetes. (b) The Arkansas Medicaid Program shall provide coverage for a continuous glucose monitor for the treatment of an individual if the individual has: (1) Either: (A) A presence of type 1 diabetes or any other type of diabetes with: (i) The use of insulin more than two (2) times daily; or (ii) Evidence of Level 2 or Level 3 hypoglycemia; or (B) Diagnosis of glycogen storage disease type 1a; and (2) Regular follow-up visits with a healthcare provider at a minimum of every six (6) months to assess for ongoing benefit of the continuous glucose monitor. (c) Coverage for a continuous glucose monitor under the Arkansas Medicaid Program shall allow the beneficiary to obtain a continuous glucose monitor through a prescription at a pharmacy and be eligible for rebates as a pharmacy benefit. Added by Act 2023, No. 393,§ 2, eff. 8/1/2023. Added by Act 2023, No. 205,§ 8, eff. 8/1/2023. (a) As used in this section, "continuous glucose monitor" means an instrument or device, including repair and replacement parts, that: (1) Is designed and offered for the purpose of aiding an individual with diabetes; (2) Measures glucose levels at set intervals by means of a small electrode placed under the skin and held in place by an adhesive; and (3) Is generally not useful to an individual who has not been diagnosed with diabetes. (1) Is designed and offered for the purpose of aiding an individual with diabetes; (2) Measures glucose levels at set intervals by means of a small electrode placed under the skin and held in place by an adhesive; and (3) Is generally not useful to an individual who has not been diagnosed with diabetes. (b) The Arkansas Medicaid Program shall provide coverage for a continuous glucose monitor for the treatment of an individual if the individual has: (1) Either: (A) A presence of type 1 diabetes or any other type of diabetes with: (i) The use of insulin more than two (2) times daily; or (ii) Evidence of Level 2 or Level 3 hypoglycemia; or (B) Diagnosis of glycogen storage disease type 1a; and (2) Regular follow-up visits with a healthcare provider at a minimum of every six (6) months to assess for ongoing benefit of the continuous glucose monitor. (1) Either: (A) A presence of type 1 diabetes or any other type of diabetes with: (i) The use of insulin more than two (2) times daily; or (ii) Evidence of Level 2 or Level 3 hypoglycemia; or (B) Diagnosis of glycogen storage disease type 1a; and (A) A presence of type 1 diabetes or any other type of diabetes with: (i) The use of insulin more than two (2) times daily; or (ii) Evidence of Level 2 or Level 3 hypoglycemia; or (i) The use of insulin more than two (2) times daily; or (ii) Evidence of Level 2 or Level 3 hypoglycemia; or (B) Diagnosis of glycogen storage disease type 1a; and (2) Regular follow-up visits with a healthcare provider at a minimum of every six (6) months to assess for ongoing benefit of the continuous glucose monitor. (c) Coverage for a continuous glucose monitor under the Arkansas Medicaid Program shall allow the beneficiary to obtain a continuous glucose monitor through a prescription at a pharmacy and be eligible for rebates as a pharmacy benefit.
‹ Prev All Arkansas sections Next ›
Lexace provides legal information, not legal advice, and no attorney–client relationship is created. Statute text is provided for general information and may not reflect the most recent amendments; verify against the official state code.